Clinical evaluation of hexamethylmelamine (NSC-13875).
D000328:Adult; D000368:Aged; D000588:Amines / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001772:Blood Cell Count; D001792:Blood Platelets; D001796:Blood Protein Disorders / Q000139:chemically induced; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006400:Hematocrit; D006801:Humans; D007958:Leukocyte Count; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000473:pathology; D009461:Neurologic Manifestations; D013997:Time Factors; D014227:Triazines / Q000009:adverse effects / Q000627:therapeutic use*
D000588:Amines; D000970:Antineoplastic Agents; D014227:Triazines